Utilizing Rationally Designed Photosensitizers to Drive Divergent Immunogenic Cell Death in Photoimmunotherapy

Area of Science:

• Oncology
• Immunology
• Materials Science

Background:

• Photoimmunotherapy combines photodynamic therapy (PDT) and immunotherapy for cancer treatment.
• Organic photosensitizers can induce immunogenic pyroptosis, enhancing anti-tumor immune responses.
• The relative immunogenic potential of type I and type II PDT pathways is not well understood.

Purpose of the Study:

• To systematically compare the immunogenic potential of type I and type II photodynamic therapy.
• To develop a rational design strategy for organic photosensitizers for photoimmunotherapy.

Main Methods:

• Engineered A-D-A structured organic photosensitizers with tunable intramolecular charge transfer.
• Investigated photodynamic pathways (Type I vs. Type II) and their effect on pyroptosis induction.
• Assessed immune activation, systemic anti-tumor response, and distant tumor suppression.

Main Results:

• Type I-dominant photosensitizers more effectively trigger caspase-1-mediated pyroptosis compared to type II-dominant ones.
• Pyroptosis induced by type I PDT releases damage-associated molecular patterns and pro-inflammatory factors, activating the immune system.
• The lead type I photosensitizer demonstrated significant systemic anti-tumor immunity and suppressed distant tumors under low-power near-infrared irradiation.

Conclusions:

• Type I and Type II photodynamics have distinct roles in immune response activation.
• Type I-dominant photosensitizers are superior for inducing pyroptosis and potent anti-tumor immunity in photoimmunotherapy.
• This study provides a rational design framework for developing next-generation photoimmunotherapy agents.